Impact of Cilostazol Versus Cilostazol and Selenium Combination on the Healing of Diabetic Foot Ulcer Patients
Key facts
- Who runs it
- Ain Shams University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2/3
- People taking part
- 206 people enrolled
- Started
- 19 Oct 2023
- Ended
- 30 Jan 2025
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Cilostazol
- Selenium
- Record updated
- 18 February 2025
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (10)Hide the full registry criteria
Who can take part
- Eligible patients will be adult diabetic patients aged 18 years and older with non-ischemic diabetic foot ulcers Wagner's grade 2, 3, and 4
Who cannot take part
- Patients who take medications that interfere with wound healing (glucocorticoids, immunosuppressive and cytotoxic drugs) at the time of inclusion
- Patients with Cilostazol or Selenium allergy
- Patients with Cilostazol contraindications (Heart Failure, bleeding disorder)
- Patients with a history of comorbidities that interfere with wound healing (cancers, congestive heart failure, end-stage renal disease, and liver failure)
- Presence of clinical signs of active infection unresponsive to oral antibiotics (oedema, erythema, discharge, regional lymph node enlargement, pain, or fever)
- Patients with poor glycemic control at the time of inclusion (HbA1c>12%)
- Wagner's grade 5 patients (because of the indications for amputation)
- Patients who need either direct graft or indirect revascularization procedure during the study
- Non-diabetic patients with foot wounds due to vascular or dermatological reasons
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The growing incidence of DM can lead to the increased prevalence of diabetic foot complications, which have become a serious medical, social, and economic concern of global importance. this study aims to find a novel intervention that improve wound healing in diabetic foot ulcer to improve patients' quality of life, reduce amputation rate, and reduce the mortality rate among diabetic foot ulcer patients
The 3 groups in the trial
- Control GroupNo study treatment, for comparison
patients will receive standard wound care and diabetes management (that includes bed rest with elevation, antibiotics, analgesics, and dressings).
- Cilostazol GroupExisting treatment, for comparison
patients will receive Cilostazol 100 mg tablets per oral once daily in addition to standard wound care and diabetes management.
Treatment: Cilostazol
- Cilostazol & Selenium GroupExisting treatment, for comparison
Cilostazol 100 mg tablets plus Selenium 200 mcg tablets per oral once daily, in addition to standard wound care and diabetes management.
Treatment: Cilostazol and Selenium
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Impact of Cilostazol Versus Cilostazol and Selenium Combination on the Healing of Diabetic Foot Ulcer Patients: a Randomized Controlled Trial
- Publications
- Impact of Cilostazol versus Cilostazol and Selenium Combination on The Healing of Diabetic Foot Ulcer Patients: A Randomized Controlled Trial.Diabetology & metabolic syndrome, 2026
- Record updated
- 18 February 2025